Healthy Clinical Trial
Official title:
The Effect of Functional Dairy Products Enriched With Dietary Fibers on Human Health and Gut Microbiota
Verified date | March 2021 |
Source | Center of Food and Fermentation Technologies |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this dietary intervention is to study the effects of dietary fibers on the gut microbiota and use yoghurt as the carrier. Hypothesis 1: Intake of dietary fibers improves the blood lipid profile of the participants. Hypothesis 2: Intake of dietary fibers stabilizes the gut microbiome (e.g., low diversity) of the participants, improves gut health and normalizes gastrointestinal function and bowel habits.
Status | Completed |
Enrollment | 90 |
Est. completion date | August 31, 2020 |
Est. primary completion date | August 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 55 Years |
Eligibility | Inclusion Criteria: - Age 25-55 - Normal bowel function - Regular consumer of dairy products, willing to consume dairy products daily for 2 weeks - Ability to provide a signed written informed consent - Willing to provide stool and blood specimens 2 times over the 2-week study period Exclusion Criteria: - Diagnosed history of chronic diseases including coronary heart disease, stroke, cancer, type 1 or 2 diabetes mellitus, inflammatory bowel disease, gastritis, autoimmune disease, or rheumatoid arthritis - Medication: statins, blood pressure medications, antidepressants, other prescription medications - History of bariatric operation, removal of the gallbladder. - Food allergies, lactose intolerance - Recent (previous 3 months) use of antibiotics - Intake of highly dosed pre- or probiotics 2 weeks prior and during the study - Current pregnancy or breastfeeding - Volunteers showing previously unrecognized illness will also be excluded - Individual unable to give informed consent |
Country | Name | City | State |
---|---|---|---|
Estonia | Center of Food and Fermentation Technologies | Tallinn | Harjumaa |
Lead Sponsor | Collaborator |
---|---|
Center of Food and Fermentation Technologies | AS FARMI Piimatööstus, Jõhvi, Estonia, SYNLAB Eesti OÜ, Tallinn, Estonia |
Estonia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of the intestinal microbiota | Fecal microbiota analysis based on the 16S rRNA sequencing pre- and post-dietary intervention. | 14 days | |
Primary | Evaluation of blood lipid profile | Triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol pre- and post-dietary intervention in plasma (mmol/L). | 14 days | |
Primary | Evaluation of blood glucose levels | Fasting glucose pre- and post-dietary intervention in plasma (mmol/L). | 14 days | |
Secondary | Evaluation of the stool form | Stool form will be assessed using a validated 7-point scale called Bristol Stool Form Scale pre- and post-dietary intervention. | 14 days | |
Secondary | Evaluation of the defecation frequency | Evacuation frequency during 3 days pre- and post-dietary intervention.
Evacuation frequency (number of bowel movements per week) pre- and post-dietary intervention. |
14 days | |
Secondary | Evaluation of the defecation timing | Evacuation timing 3 days before sampling pre- and post-dietary intervention. | 14 days | |
Secondary | Evaluation of the gastrointestinal symptoms | Frequency and severity of the gastrointestinal symptoms (Constipation, Diarrhea, Bloating, Flatulence, Cramps, Stomach pain). Scale of frequency: Never, Less than 10 times a year, Once a month, Once a week, Every day. Scale of severity: I do not have any gastrointestinal symptoms, Mild (does not disturb), Moderate, Strong (disturbs considerably). | 14 days | |
Secondary | Evaluation of the blood vitamin D status | 25-OH vitamin D pre- and post-dietary intervention in plasma. | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |